VERU Veru Inc

$VERU First patient in for Plateau trial was March 9th. That means the first patients from the trial should be getting their 32 week progress documented from this week forward.

Oppenheimer reiterated its Outperform rating on Veru and maintained its $24 price target, reaffirming confidence in enobosarm, the company’s lead obesity-treatment candidate, ahead of a key clinical data update. The analyst expects an interim analysis of the Phase 2b PLATEAU trial, which evaluates enobosarm in combination with semaglutide, to show significant preservation of lean body mass and greater fat loss compared with semaglutide alone. Positive findings could substantially reduce investment risk ahead of the full primary data readout expected in Q4 2027. The trial is fully enrolled with 239 patients, exceeding its original target of 200 participants. Veru also holds a key U.S. patent covering enobosarm and semaglutide combination regimens, with protection expected to extend at least through October 2044, potentially strengthening the program’s long-term commercial positioning. $VERU

$VERU From 240 to 2. Veru has had 99% loss of stock price. Normality starts at 50+ . There is +2500% needed to arrive there. Price target 24 is very low it is s only 2.4 before the reverse split. Under 10 this scam company should not even be allowed to trade

$VERU $.20 split adjusted. What do I do with all this shareholder value, Mitch?!?!? Please give yourselves end of year bonuses and more shares. You all deserve it for all the shareholder value you have created over 10 years of doing nothing but wasting our money to enrich yourselves.

$VERU Also, for Lilly, double the weight loss probably means double the muscle loss, but yeah I'm not sure what they could acquire to solve that either.

$VERU what do all of these “executives” do all day while their ONLY trial is ongoing?!?!? Half of Veru’s 20 (total) employees receive executive pay, why?? What are they overseeing? What value are they adding? Why is the BOD not acting in the best interest of shareholders??!?!!?

$VERU more bad NVO news with retatrutide. Nice! so, NVO really needs something. wonder what they could develop or acquire to turn the tide.

$VERU Novo’s CEO told Fierce that the company remains on the hunt for deals that “close some of the gaps” in its pipeline....When asked by Fierce this morning whether he agreed with reporting that investors had been underwhelmed by the company’s deal-making strategy, Doustdar said Novo was still on the hunt for acquisitions. “We continue, of course, to mention that we are looking and searching across all of our therapy areas for innovation that fits and closes, maybe, some of the gaps that we have, as well as, of course, synergizes with what we're doing ourselves,” the CEO responded. “We remain disciplined,” Doustdar continued. “I think, for us, it’s not about running and making sure we close a certain number of deals just to satisfy the headline news.” “For us, it really starts [by] mak[ing] sure that we deeply search into what is strategically fitting into our portfolio of products and our strategy, and we'll continue doing that.”

$VERU Ketamine-free, one of the NRXP drugs, has received FDA approval. However, the stock price is moving in the opposite direction. Today is the opportunity. lets go to the moon fda approved $NRXP omg

$VERU Read this so you don't have to. Nothing new. Pretty surface level, and still references Veru's old indication for Sabiz, not the recent KRAS pivot, but accurate in that Veru potentially faces a reckoning at the interim. The part they missed is that the interim will only show DEXA, not incremental or function, which are the real prize. Quality already showed great DEXA results, and in older patients(60+) , and BMI mostly 30+. Plateau is slightly older and heavier(65+ and BMI over 35), but I don't see the stock rerating on those results which would lead to bad financing(given how the stock is sliding), and a bad negotiation position even if there was partnering interest at that point.